Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 7/20 | 0.37 |
| ▸ | DRD2 | P14416 | 6/20 | 0.37 |
| ▸ | DRD3 | P35462 | 3/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13343856 | 0.82 | PARP1 (0.49) | PARP1NR3C2MMP12DRD4DRD2 | |
| SCHEMBL14072147 | 0.81 | PARP1 (0.48) | PARP1NR3C2MMP12DRD4DRD2 | |
| SCHEMBL351961 | 0.81 | PARP1 (0.72) | PARP1NR3C2MMP12DRD4DRD2 | |
| Hydrochloric Acid SCHEMBL3557170 | 0.79 | PARP1 (0.70) | PARP1NR3C2MMP12DRD4DRD2 | |
| SCHEMBL13377721 | 0.77 | PARP1 (0.44) | PARP1NR3C2MMP12DRD4DRD2 | |
| SCHEMBL13343857 | 0.77 | PARP1 (0.44) | PARP1NR3C2MMP12DRD4DRD2 | |
| SCHEMBL13377715 | 0.74 | PARP1 (0.42) | PARP1NR3C2MMP12DRD4DRD2 | |
| SCHEMBL13383406 | 0.74 | PARP1 (0.42) | PARP1NR3C2MMP12DRD4DRD2 | |
| SCHEMBL13343858 | 0.74 | PARP1 (0.42) | PARP1NR3C2MMP12DRD4DRD2 | |
| SCHEMBL13343876 | 0.73 | PARP1 (0.38) | PARP1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7691851-B2 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
| WO-2008109177-A2 | METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221091-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008063668-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | PARP1 156/4885NR3C2 2202/4885MMP12 8/4885 |
| US-20080221091-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP12, MMP13, MMP25 | PARP1 314/4885NR3C2 3143/4885MMP12 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.